Announcing a new publication for Acta Materia Medica journal. Phosphodiesterase-4 (PDE4), a member of the phosphodiesterase ...

Learn how Deanna Wallin turned her personal struggles into the thriving Naples Soap Company. Discover the power of resilience ...

Chelsea and Westminster Hospital are revolutionising detection by using an iPhone app that reduces clinican time by 75% ...

Less than a quarter of patients diagnosed with mild psoriasis had a body surface area of less than 3% at the time of diagnosis.

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...

A big freckle or a sunspot? A flat mole or a dark freckle? Here’s how to tell the difference between the three – and when to ...

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugsRamat Gan, Israel, March 24, 2025 (GLOBE ...

Patients with skin disease adhering to a proper diet may experience better treatment responses and a reduced risk of adverse ...

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found bimekizumab to have benefits beyond safety ...